• Mashup Score: 9
    SCAI Statement on FDA Circulatory Systems Devices Panel on RDN Systems | SCAI - 8 month(s) ago

    On August 22 and August 23, 2023, the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) convened panels of the Medical Device Committee to review scientific evidence on interventions aimed at reducing blood pressure in patients with hypertension (HTN). The panel discussed, made recommendations and voted on information regarding the premarket approval applications (PMA) for two renal denervation (RDN) systems as tools to reduce blood pressure in adults with uncontrolled HTN,

    Source: scai.org
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of SrihariNaiduMD
      SrihariNaiduMD

      RT @SCAI: Just released—read SCAI's Statement on FDA Circulatory Systems Devices Panel on RDN Systems ➡️ https://t.co/85trdtlvbl #CardioNe…

    • Profile photo of SCAI
      SCAI

      Just released—read SCAI's Statement on FDA Circulatory Systems Devices Panel on RDN Systems ➡️ https://t.co/85trdtlvbl #CardioNews #CardioTwitter #RenalDenervation #RDN #InterventionalCardiology #hypertension https://t.co/J8K5kG7lmX

  • Mashup Score: 0
    New SCAI Position Statement Highlights the Role of Renal Denervation in Hypertension Treatment - 8 month(s) ago

    August 21, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) has released a position statement on Renal Denervation (RDN), emphasizing patient selection, optimal techniques, competence, training, and institutional recommendations. The statement was published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI).    Despite advocacy for lifestyle interventions and the availability of medications to address hypertension (HTN), more than one half of individuals with high blood pressure do not achieve recommended treatment goals. RDN, a minimally invasive procedure targeting sympathetic nerves adjacent to the renal arteries, has shown promising results in reducing blood pressure.   Hypertension is a leading cause of death and disability globally, and the prevalence of uncontrolled HTN is on the rise. The impact of cost, side effects, and polypharmacy on quality-of-life often limit access and adherence to pharmacotherapy. Therapies targe

    Source: www.dicardiology.com
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DAICeditor
      DAICeditor

      @DAICeditor @SCAI @MyJSCAI #SCAI has released a position statement on #RenalDenervation (#RDN), emphasizing patient selection, optimal techniques, competence, training, and institutional recommendations: https://t.co/B7qwkXiVcI

Load More